<DOC>
	<DOCNO>NCT02706483</DOCNO>
	<brief_summary>Multi-center , open-label , long-term safety study</brief_summary>
	<brief_title>Long Term Safety Study Plecanatide</brief_title>
	<detailed_description>This phase 3 , multicenter , open-label , long-term safety tolerability study 6 mg daily dose plecanatide administer orally . Patients Study Completers Eligible Screen Failures whose eligibility confirm end participation double-blind plecanatide study SP304203-04 SP304203-05 enrol . Beginning Day 1 , patient take one ( 1 ) plecanatide 6.0 mg tablet clinic thereafter every morning approximately 240 mL ( 8 ounce ) liquid , without meal . Safety tolerability assessment patient ' self-assessment disease severity perform accord Schedule Assessments . Patients discontinue early study undergo Early Withdrawal ( EW ) visit within 5 day stop study drug .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patients document diagnosis IBSC : Completed plecanatide study SP30420304 SP30420305 , compliant previous study 's requirement , experience Serious Adverse Event ( SAE ) deem related study drug course previous study , OR Failed screen study SP30420304 SP30420305 due diary noncompliance ( exclusion core study ) due administrative reason allow enter study notification Sponsor delegate . Key Patient unwilling unable : participate study require duration , understand sign inform consent form ( ICF ) undergo protocol related test procedure throughout study . Female patient childbearing potential positive urine pregnancy test Day 1 . Male female patient childbearing potential agree continue use method birth control use core doubleblind plecanatide study duration clinical trial . Patient experience significant negative change health status course participation core doubleblind plecanatide study completion study . In opinion Investigator Medical Monitor , patient 's best interest participate study . The reason ( ) patient 's exclusion must specify .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>